Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response

Area of Science:

• Neurology
• Clinical Pharmacology
• Epileptology

Background:

• Intravenous valproate (VPA) is a standard treatment for status epilepticus (SE).
• Optimal VPA loading doses for SE have not been fully established.
• Understanding dose-response relationships is crucial for effective SE management.

Purpose of the Study:

• To analyze the correlation between VPA loading dose and plasma levels with clinical response in SE.
• To determine if higher VPA loading doses improve treatment outcomes in SE patients.
• To identify an adequate VPA loading dose range for SE treatment.

Main Methods:

• Retrospective study of VPA-naïve SE episodes treated with VPA.
• Data collected from January 2013 to June 2019 at a single referral center.
• Correlated VPA loading dose and trough plasma levels with clinical response and mortality, adjusting for confounders.

Main Results:

• Out of 128 SE episodes, 53 (41%) responded to VPA.
• Median VPA loading dose was 25.2 mg/kg; higher doses (>30 mg/kg) were not associated with increased response rates.
• Neither loading dose nor plasma levels correlated with response probability or mortality.

Conclusions:

• High VPA loading doses (>30 mg/kg) do not enhance response rates in SE.
• A VPA loading dose of 25-30 mg/kg appears sufficient for SE treatment.
• Further studies are needed to confirm these findings and optimize VPA dosing strategies.